/Incyte%20Corp_%20logo%20and%20bar%20chart-by%20Piotr%20Swat%20via%20Shutterstock.jpg)
Valued at a market cap of $11.5 billion, Incyte Corporation (INCY) is a biopharmaceutical company that discovers, develops, and commercializes novel medicines to address serious unmet medical needs, particularly in oncology, inflammation, and autoimmunity. The Wilmington, Delaware-based company is expected to announce its fiscal Q1 earnings for 2025 before the market opens on Tuesday, Apr. 29.
Prior to this event, analysts project this biopharmaceutical company to report a profit of $0.75 per share, up 97.4% from $0.38 per share in the year-ago quarter. The company has missed Wall Street's bottom-line estimates in each of the last four quarters. Its earnings of $1.09 per share in the previous quarter fell short of the consensus estimates by 15.5%.